The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
This $999,994 cooperative agreement from the National Science Foundation under the Technology, Innovation, and Partnerships program will support Deepconvo Inc.'s development of voice-based telehealth products and services for respiratory disease monitoring and screening. Deepconvo will further develop its chronic obstructive pulmonary disease early exacerbation warning system to more accurately measure lung function deterioration through voice and breath data captured on mobile phones. Key...
Grant Award Summary Spiromatics, Inc. received a $471,544 Project Grant from the National Institute of Environmental Health Sciences under the Medical Library Assistance program (CFDA 93.879) for the period of September 16, 2025 through September 15, 2026. The company is developing novel technologies to address the significant diagnostic gap in obstructive lung disease detection, where approximately 70% of individuals with spirometry-defined obstruction remain undiagnosed. The primary...
Precision Theranostics Inc. was awarded a $256,000 Small Business Innovation Research Phase I Project Grant by the National Science Foundation Division of Industrial Innovation. The grant supports the development of a lung health diagnostic test for chronic obstructive pulmonary disease and prognosis-based early intervention from May 1, 2021 to April 30, 2022. The grant falls under the National Science Foundation's Engineering program (CFDA 47.041), which seeks to improve quality of life and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Makani Science Inc. will develop a continuous respiratory monitoring platform to accurately classify apnea of prematurity (AOP) in premature newborns. The $371,021 award will fund a two-phase effort to build a multimodal monitoring system and machine learning models to identify the major AOP types (central, obstructive, and mixed). The initial R61 phase will develop the...
The National Institute of Child Health and Human Development awarded The Johns Hopkins University $523,526 through the Child Health and Human Development Extramural Research program (CFDA 93.865) on September 4, 2025, to develop and implement a pediatric artificial intelligence multi-modal digital stethoscope and respiratory surveillance system in South Africa. The project, which extends through August 31, 2028, comprises two phases: an R21 exploratory phase focused on developing and...
Federal Grant Award Summary Airalux Medical, Inc. received a $306,872 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, through September 4, 2026. The company is developing a digitally enhanced incentive spirometer device designed to improve patient adherence to post-operative respiratory therapy and streamline clinical workflows. The device combines advanced sensors and...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $274,274 to X-Cor Therapeutics Inc., a minority-owned small disadvantaged business in Washington, DC, to develop a novel respiratory dialysis system for treating chronic obstructive pulmonary disease (COPD) patients. The project aims to optimize a prototype that can efficiently remove excess carbon dioxide from the blood of COPD patients, with the goal of...
The National Science Foundation (NSF) awarded a $305,000 STTR Phase I project grant to Sensvita Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a non-invasive radio frequency sensing technology for home-based monitoring of heart and lung function. The proposed system uses advanced sensing methods to measure critical physiological parameters without the need for skin contact or maintenance, improving the convenience, scalability,...
Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $108,003 to the University of California, San Diego on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on early detection of chronic obstructive pulmonary disease (COPD) through advanced imaging technology. The project, extending through May 31, 2027, develops a novel ultrashort echo-time (UTE) magnetic resonance imaging (MRI) technique, specifically...
A BREAKTHROUGH MOBILE PHONE TECHNOLOGY THAT AIDS IN EARLY DETECTION OF COPD - PROJECT SUMMARY / ABSTRACT COPD IS THE FOURTH LEADING GLOBAL KILLER, IN PART, BECAUSE OF THE FAILURE OF FRONTLINE MEDICINE TO DETECT THE DISEASE. POOR EARLY DETECTION LEADS TO UNFAVORABLE OUTCOMES AND HIGH HEALTHCARE COSTS. TELE-STETHOSCOPE* OR "TS" IS NOVEL TECHNOLOGY THAT ALLOWS ACOUSTIC DATA CAPTURED FROM ORDINARY MOBILE PHONES TO PERFORM ROBUST ANALYSIS OF HEMODYNAMICS AND PNEUMODYNAMICS. TS IS INTENDED TO BE USED IN PRIMARY CARE PARTICULARLY IN TELE-HEALTH AND BEFORE SCHEDULED PHYSICAL EXAMINATION. ITS PURPOSE IS TO ALERT PRIMARY CARE PHYSICIANS TO THE NEED FOR PHYSICAL EXAMINATION AND POSSIBLY REFERRAL. IN THESE SITUATIONS, THERE ARE NO OTHER COMPARABLE TESTING OPTIONS. TS HAS THREE IMPORTANT INNOVATIONS. FIRST, IS A CLINICAL USE INNOVATION WHICH BRINGS REMOTE, IMPROMPTU PATIENT EVALUATION TO ANYONE WITH A SMARTPHONE. CUSTOMER DISCOVERY HAS VALIDATED BOTH A WORKFLOW AND REIMBURSEMENT STRATEGY CONSISTENT WITH COMMERCIAL SUCCESS. FURTHER, FDA GUIDANCE SUGGESTS VIABILITY OF AGENCY CLEARANCE. SECOND IS TS'S NOVEL APPROACH TO MAKING AI ALGORITHMS. TS USES ACOUSTIC DATA, CAPTURED BY OEM PHONE MICROPHONES, INTO RIGOROUS, PHYSICS-BASED FEATURES THAT DESCRIBE ORGAN HEMODYNAMICS AND PNEUMODYNAMICS. THE FEATURES OR INDEPENDENT VARIABLES ARE THEN USED TO CREATE BINARY CLASSIFICATION MODELS WITH LOGISTIC REGRESSION. BY RELYING ON PHYSICS, TS NEVER HAS TO USE NEURAL NETWORKS OR OVERFITTING STRATEGIES THAT HAVE RAISED CONCERNS ABOUT DATA INTENSITY, MODEL STABILITY, REGULATORY TRANSPARENCY AND UNKNOWN RELIABILITY. THE THIRD INNOVATION IS THAT, BY RELYING ON PASSIVE ACOUSTIC DATA, TS CLASSIFIES ORGAN FUNCTION BY OBSERVING ORGAN DYNAMICS DIRECTLY RATHER THAN FROM FORCED AIR CAPACITY. TS USES MANY IDEAS FROM PHYSICS THAT WERE NOT AVAILABLE UNTIL FAIRLY RECENTLY. BY RELYING ON DYNAMICS, TS OFFERS A NOVEL APPROACH TO FORCED AIR THAT MAY EVENTUALLY BE ADDITIVE TO OUR UNDERSTANDING OF RESPIRATORY CONDITIONS EVEN IN PFT LABS. THIS WILL BE THE THIRD LARGE SCALE HUMAN STUDY THAT DEMONSTRATES CLASSIFICATION OF CARDIO - PULMONARY FUNCTIONALITY. IT FOLLOWS A PUBLISHED STUDY ON COVID DETECTION AS WELL AS SOON TO BE PUBLISHED STUDY ON THE ABILITY OF TS TO REPRODUCE ECHOCARDIOGRAM ESTIMATES OF EJECTION FRACTION. ANALYSIS OF STETHOSCOPE RECORDINGS SUGGESTS THAT THE COPD DIAGNOSTIC WILL RELY ON A COMBINATION OF RIGHT HEART SIDE HEMODYNAMICS AND LOW FREQUENCY LUNG PNEUMODYNAMICS. A SIGNIFICANT BODY OF RESEARCH IS PRESENTED WHICH VALIDATES THE USE OF MOBILE PHONES AS AN AUSCULTATION DEVICE WITH THE ABILITY TO DETECT AND DIAGNOSIS COPD. THE AIM OF THIS STUDY IS TO DEVELOP, EVALUATE, AND TEST AN ALGORITHM THAT ALLOWS ORDINARY MOBILE PHONES TO DETECT COPD. OUR HYPOTHESIS IS THAT TS TECHNOLOGY CAN DETECT COPD BY MATCHING PHONE ACOUSTIC RECORDINGS TO DIAGNOSIS. DIAGNOSIS WILL BE DETERMINED BY A PHYSICIAN AFTER CONSIDERING GOLD STANDARD TESTING. PERFORMANCE OF THE MODELS WILL BE EVALUATED BY USING COMMON STATISTICAL APPROACHES SUCH AS AREA UNDER THE RECEIVER OPERATING CURVE AUC, SENSITIVITY, SPECIFICITY, ACCURACY. THE RESEARCH WILL HAVE 3 MILESTONES BASED ON RECRUITMENT OF 30, 60 AND 100 PATIENTS RESPECTIVELY. OUR APPROACH IS BASED ON RECRUITMENT FROM PATIENTS ASSIGNED TO A HOSPITAL PFT LAB SO THAT RECORDINGS AND GOLD STANDARD TESTING ARE DONE CONCURRENTLY. OUR TEAM CONSISTS OF A BROAD RANGE OF TALENT INCLUDING THE INVENTOR OF TS, PULMONOLOGY EXPERTISE, THE RESEARCH DIRECTOR OF EMERGENCY MEDICINE FOR THE HOSPITAL RUNNING THE TESTS, STATISTICAL EXPERTISE, AND PROJECT MANAGEMENT. * TELE-STETHOSCOPE OR "TS" IS PATENT PENDING TECHNOLOGY DEVELOPED BY FLEMING SCIENTIFIC.